Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UV1 vaccine plus pembrolizumab in first-line PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma
2020-005910-17Phase 2Completed
- Sponsor
- Martin Luther University Halle-Wittenberg
- Start
- Feb 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of UV1, pembrolizumab and sargramostim in head and neck squamous cell carcinoma (HNSCC), sponsored by Martin Luther University Halle-Wittenberg. Primary endpoint: Progression-free survival rate at 6 months. Started Feb 2021; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2020-005910-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005910-17.